中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

60 records (took 0.069 seconds)

    CYSTEINE ENGINEERED FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES
    31.
    发明申请
    CYSTEINE ENGINEERED FIBRONECTIN TYPE III DOMAIN BINDING MOLECULES 有权

    公开(公告)号：US20210301025A1

    公开(公告)日：2021-09-30

    申请号：US17303425

    申请日：2021-05-28

    Applicant: Janssen Biotech, Inc.

    Inventor： Shalom GOLDBERG ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

    IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78

    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

    Cysteine engineered fibronectin type III domain binding molecules
    33.
    发明授权
    Cysteine engineered fibronectin type III domain binding molecules 有权

    公开(公告)号：US10196446B2

    公开(公告)日：2019-02-05

    申请号：US14512801

    申请日：2014-10-13

    Applicant: Janssen Biotech, Inc.

    Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin ,  Karyn O'Neil

    IPC: C07K16/28 ,  G01N33/74 ,  C07K14/78 ,  A61K39/00

    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

    FIBRONECTIN TYPE III DOMAIN BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
    34.
    发明申请
    FIBRONECTIN TYPE III DOMAIN BASED SCAFFOLD COMPOSITIONS, METHODS AND USES 审中-公开

    公开(公告)号：US20180334492A1

    公开(公告)日：2018-11-22

    申请号：US16032691

    申请日：2018-07-11

    Applicant: Janssen Biotech, Inc.

    Inventor： Steven Jacobs ,  Karyn O'neil

    IPC: C07K14/78

    CPC classification number: C07K14/78 ,  C40B40/08 ,  C40B50/06

    Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.

    Stabilized Fibronectin Domain Compositions, Methods and Uses
    36.
    发明申请
    Stabilized Fibronectin Domain Compositions, Methods and Uses 审中-公开
    稳定的纤连蛋白结构域组成，方法和用途

    公开(公告)号：US20160244744A1

    公开(公告)日：2016-08-25

    申请号：US14969361

    申请日：2015-12-15

    Applicant: Janssen Biotech, Inc.

    Inventor： Steven Jacobs

    IPC: C12N15/10 ,  C07K16/18 ,  C07K14/78

    CPC classification number: C12N15/1044 ,  A61K38/00 ,  C07K14/78 ,  C07K16/18 ,  C07K2318/20 ,  Y02A50/473

    Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof, exhibit enhanced thermal and chemical stability while presenting six modifiable loop domains which can be engineered to form a binding partner capable of binding to a target for applications in diagnostic and/or therapeutic compositions, methods and devices.

    Abstract translation: 基于纤连蛋白III（FN3）蛋白的共有序列的蛋白质支架，例如来自人纤连蛋白（人腱生蛋白）的第十FN3重复序列，包括编码蛋白质支架的分离的核酸，载体，宿主细胞和制备方法 并且其使用表现出增强的热和化学稳定性，同时呈现六个可修饰的环结构域，其可被工程化以形成能够结合靶标的结合配偶体，用于诊断和/或治疗组合物，方法和装置中的应用。

    IL4/IL13 binding repeat proteins and uses
    37.
    发明授权
    IL4/IL13 binding repeat proteins and uses 有权
    IL4 / IL13结合重复蛋白和用途

    公开(公告)号：US09206244B2

    公开(公告)日：2015-12-08

    申请号：US14225821

    申请日：2014-03-26

    Applicant: Janssen Biotech, Inc.

    Inventor： Michael Baumann ,  Gaby Tresch ,  Steven Jacobs ,  Karyn O'Neil

    IPC: C07K14/705 ,  C07K14/47 ,  A61K38/00

    CPC classification number: C07K14/705 ,  A61K38/00 ,  C07K14/47 ,  C07K2319/70 ,  Y02A50/409 ,  Y02A50/423

    Abstract: IL4/IL13-binding proteins comprise binding domains, which inhibit IL4/IL13 binding to IL4Ralpha and common gamma chain complexes (Type 1) and inhibit IL4 binding to IL4Ralpha and IL13Ralpha1 complexes (Type 2), and IL13 binding to IL13Ralpha1 and/or IL13Ralpha2, are useful in the treatment of cancer, inflammatory, and other pathological conditions, such as allergic or fibrotic conditions, especially pulmonary conditions.

    Abstract translation: IL4 / IL13结合蛋白包含结合结构域，其抑制IL4 / IL13与IL4Rα和常见的γ链复合物（1型）结合并抑制IL4与IL4Rα和IL13Rα1复合物（2型）的结合，IL13与IL13Rα1和/或IL13Rα2的结合 ，可用于治疗癌症，炎症和其他病理状况，如过敏或纤维化病症，特别是肺部疾病。

    Cysteine Engineered Fibronectin Type III Domain Binding Molecules
    38.
    发明申请
    Cysteine Engineered Fibronectin Type III Domain Binding Molecules 审中-公开
    半胱氨酸工程化纤连蛋白III型结构分子

    公开(公告)号：US20150104808A1

    公开(公告)日：2015-04-16

    申请号：US14512801

    申请日：2014-10-13

    Applicant: JANSSEN BIOTECH, INC.

    Inventor： Shalom Goldberg ,  Steven Jacobs ,  Tricia Lin

    IPC: C07K16/28 ,  G01N33/74 ,  C07K14/435

    CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K14/78 ,  C07K2317/31 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2318/20 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  G01N33/74

    Abstract: Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.

    Abstract translation: 通过诱变母体分子的核酸序列并用半胱氨酸代替一个或多个氨基酸残基来编码半胱氨酸来制备含有一个或多个游离半胱氨酸氨基酸的半胱氨酸改造的单特异性和双特异性EGFR和/或c-Met FN3结构域的分子， 设计的含有单特异性或双特异性分子的FN3结构域; 表达含有半胱氨酸的FN3结构域的分子; 并回收含有半胱氨酸的FN3结构域的分子。 分离的半胱氨酸改造的单特异性或双特异性FN3结构域含有的分子可以共价连接到检测标记或药物部分，并在治疗上使用。

Patent Agency Ranking